AAK1 Inhibitor Synthesis for Scale-Up and Impurity Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing synthetic methods for the AAK1 inhibitor (S)-1-((2′,6-bis(difluoromethyl)-[2,4′-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amine are not suitable for large-scale manufacture of pharmaceutically acceptable material, as they often produce harmful byproducts, use toxic solvents, and are inefficient or dangerous when scaled up.
Innovation Solution
Developed methods for synthesizing (S)-1-((2′,6-bis(difluoromethyl)-[2,4′-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amine and its salts in quantities sufficient for human clinical trials, minimizing harmful impurities and maximizing yields, using specific reaction conditions and solvents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If existing synthetic methods are used to prepare the AAK1 inhibitor, then the compound can be made in laboratory settings, but the methods are not suitable for large-scale manufacture due to harmful byproducts, toxic solvents, and inefficiency
Solution Approach 1:
The patent changes the reaction parameters by using alternative reagents and conditions that eliminate harmful byproducts and toxic solvents while maintaining scalability. Specifically, the synthesis method uses fluorinating agents and base compounds under controlled conditions that produce high-purity product without harmful waste, enabling both laboratory and industrial production
Solution Approach 2:
The patent converts potentially harmful reaction steps into beneficial processes by selecting reagents that produce desirable outcomes. The synthesis pathway is designed to avoid harmful byproducts entirely, turning what would normally be harmful factors into advantageous features of the synthetic method, resulting in clean production suitable for both lab and scale-up
2Productivity
If existing synthetic methods are used, then the AAK1 inhibitor can be prepared, but the methods are inefficient and dangerous when scaled up
Solution Approach 1:
The patent performs preliminary optimization of reaction conditions to ensure safety and efficiency before scaling up. The synthetic method is designed with pre-established safe handling procedures, controlled reaction parameters, and optimized stoichiometry that prevent safety issues arising during scale-up while maintaining high synthesis efficiency
Solution Approach 2:
The patent introduces intermediary substances and controlled conditions that mediate the synthesis process safely. The method uses carefully selected reagents and intermediate steps that control the reaction progression, preventing runaway reactions and safety hazards while maintaining efficient synthesis rates suitable for both laboratory and industrial scales
3Manufacturing precision
If the synthesis method is optimized for high purity and minimal impurities, then pharmaceutically acceptable material is produced, but the process complexity increases
Solution Approach 1:
The patent extracts and removes harmful impurities from the synthesis process by designing a pathway that inherently avoids their formation. The method selectively removes unnecessary complex purification steps by using reagents and conditions that produce clean reactions, achieving high pharmaceutical purity without excessive process complexity
Solution Approach 2:
The patent changes the synthesis parameters to achieve high purity with simplified processes. By optimizing reaction conditions, stoichiometry, and reagent selection, the method achieves pharmaceutical-grade purity without requiring complex multi-step purification procedures, balancing manufacturing precision with process simplicity
Data Source
AI summary
Methods for the synthesis of (S)-1-((2′,6-bis(difluoromethyl)-[2,4′-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amine and salts thereof are disclosed, as well as compounds useful therein.